IL-33 controls intestinal permeability and negatively regulates wound healing in the colon (11), further supporting the notion that the IL-33-IL-33R/ST2 axis may represent an effective therapeutic target in IBD. The gene discussed is IL33; the disease is inflammatory bowel disease.